drugset / Trial / NCT02212197
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, efficacy and safety of CAM2032 versus Eligard, in patients with prostate cancer. All patients will receive leuprolide acetate administered subcutaneously once monthly during 3 months.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-11
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 3.75 mg | Subcutaneous |
| Subject | Leuprolide | Other / unclassified | 7.5 mg | Subcutaneous |